Universal Biosensors Inc
ASX:UBI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.014
0.094
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Universal Biosensors Inc
Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women’s health and fertility, non-human and environmental testing using its patented platform technology and hand-held point of use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that detects specific analytes in samples as small as a droplet. Its products include Sentia, a wine analyzer, and Xprecia Prime, a coagulation analyzer. Its Hemostasis Reference Laboratory Meso Scale Discovery (MSD) multiplex platform couples immunoassay methodology with electrochemiluminescence (ECL) detection to provide measurement of a multitude of different cytokine panels. Its laboratory services include assay validation and analysis and consultation for study design.
Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women’s health and fertility, non-human and environmental testing using its patented platform technology and hand-held point of use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that detects specific analytes in samples as small as a droplet. Its products include Sentia, a wine analyzer, and Xprecia Prime, a coagulation analyzer. Its Hemostasis Reference Laboratory Meso Scale Discovery (MSD) multiplex platform couples immunoassay methodology with electrochemiluminescence (ECL) detection to provide measurement of a multitude of different cytokine panels. Its laboratory services include assay validation and analysis and consultation for study design.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
